Advances in FIV vaccine technology

Veterinary Immunology and Immunopathology

Volumn 123, Issue 1-2, 2008, Pages 65-80

  Uhl, Elizabeth W ^a   Martin, Marcus ^b   Coleman, James K ^b   Yamamoto, Janet K ^b  

^a UNIVERSITY OF GEORGIA   (United States)

^b University of Florida College of Veterinary Medicine   (United States)

Author keywords

Feline immunodeficiency virus (FIV); Immune response; Vaccine

Indexed keywords

FELINE IMMUNODEFICIENCY VIRUS VACCINE; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; CELL PROLIFERATION; CELLULAR IMMUNITY; DRUG DESIGN; DRUG TARGETING; ENZYME LINKED IMMUNOSPOT ASSAY; EPITOPE MAPPING; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNITY; NONHUMAN; PASSIVE IMMUNIZATION; REVIEW; VIRUS CLASSIFICATION; VIRUS INFECTION;

ANIMALS; CATS; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNITY, CELLULAR; IMMUNODEFICIENCY VIRUS, FELINE; VACCINES, SUBUNIT; VIRAL VACCINES;

FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 43049173255     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2008.01.030     Document Type: Review

References (79)

1. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., Johnston M.N., Corcoran C., Wurcel A.G., Fitzpatrick C.A., Feeney M.E., Rodriguez W.R., Basgoz N., Draenert R., Stone D.R., Brander C., Goulder P.J., Rosenberg E.S., Altfeld M., and Walker B.D. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 77 (2003) 2081-2092
2. Ahmed A., and Ahmad R. HIV's evasion of host's NK cell response and novel ways of its countering and boosting anti-HIV immunity. Curr. HIV Res. 1 (2003) 295-307
3. Bachmann M.H., Mathiason-Dubard C., Learn G.H., Rodrigo A.G., Sodora D.L., Mazzetti P., Hoover E.A., and Mullins J.I. Genetic diversity of feline immunodeficiency virus: dual infection, recombination, and distinct evolutionary rates among envelope sequence clades. J. Virol. 71 (1997) 4241-4253
4. Blackard J.T., Cohen D.E., and Mayer K.H. Human immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences. Clin. Infect. Dis. 34 (2002) 1108-1114
5. Broche-Pierre S., Richardson J., Moraillon A., and Sonigo P. Evaluation of live feline immunodeficiency virus vaccines with modified antigenic properties. J. Gen. Virol. 86 (2005) 2495-2506
6. Burkhard M.J., Valenski L., Leavell S., Dean G.A., and Tompkins W.A. Evaluation of FIV protein-expressing VEE-replicon vaccine vectors in cats. Vaccine 21 (2002) 258-268
7. Calarota S.A., and Weiner D.B. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol. Rev. 199 (2004) 84-99
8. Cao H., Kank P., Sankale J.-L., Dieng-Sarr A., Mazzara G.P., Kalams S.A., Korber B., Mboup S., and Walker B.D. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development. J. Virol. 71 (1997) 8615-8623
9. + T cells in primary HIV-1 infection. J. Virol. 77 (2003) 6867-6878
10. Coleman J.K., Pu R., Martin M., Sato E., and Yamamoto J.K. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection. AIDS 19 (2005) 1457-1466
11. Dean G.A., LaVoy A., and Burkhard M.J. Peptide mapping of feline immunodeficiency virus by IFN-γ ELISPOT. Vet. Immunol. Immunopathol. 100 (2004) 49-59
12. De Groot A.S. Immunomics: discovering new targets for vaccines and therapeutics. DDT 11 (2006) 203-209
13. De Groot A.S., Sbai H., Saint Aubin C., Mcmurry J., and Martin W. Immuno-informatics: mining genomes for vaccine components. Immunol. Cell Biol. 80 (2002) 255-269
14. De Groot A.S., and Bersofsky J.A. From genome to vaccine-new immunoinformatics tools for vaccine design. Methods 34 (2004) 425-428
15. De Groot A.S., Marcon L., Bishop E.A., Rivera D., Kutzler M., Weiner D.B., and Martin W. HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine 23 (2005) 2136-2148
16. De Groot A.S., McMurry J., Marcon L., Franco J., Rivera D., Kutzler M., Weiner D., and Martin W. Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine 23 (2005) 2121-2131
17. Dunham S.P., Flynn J.N., Rigby M.A., Macdonald J., Bruce J., Cannon C., Golder M.C., Hanlon L., Harbour D.A., Mackay N.A., Spibey N., Jarrett O., and Neil J.C. Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and -18. Vaccine 20 (2002) 1483-1496
18. Dunham S.P., Bruce J., Klein D., Flynn J.N., Golder M.C., MacDonald S., Jarrett O., and Neil J.C. Prime-boost vaccination using DNA and whole inactivated virus vaccines provides limited protection against virulent feline immunodeficiency virus. Vaccine 24 (2006) 7095-7108
19. Elyar J.S., Tellier M.C., Soos J.M., and Yamamoto J.K. Perspectives on FIV vaccine development. Vaccine 15 (1997) 1437-1444
20. Finnegan C.M., Berg W., Lewis G.K., and DeVico A.L. Antigenic properties of the human immunodeficiency virus envelope during cell-cell fusion. J. Virol. 75 (2001) 11096-11105
21. Flynn J.N., Beatty J.A., Cannon C.A., Stephens E.B., Hosie M.J., Neil J.C., and Jarrett O. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus. AIDS Res. Hum. Retroviruses 11 (1995) 1107-1113
22. Flynn N.M., Forthal D.N., Harro C.D., Judson F.N., Mayer K.H., Para M.F., and The rgp120 HIV Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191 (2005) 654-664
23. Gemeniano M.C., Sawai E.T., and Sparger E.E. Feline immunodeficiency virus Orf-A localizes to the nucleus and induces cell cycle arrest. Virology 325 (2004) 167-174
24. Girard M.P., Osmanov S.K., and Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24 (2006) 4062-4081
25. Gorse G.J., Patel G.B., Mandava M.D., Belshe R.B., and National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. Vaccine-induced cytotoxic T lymphocytes against human immunodeficiency virus type 1 using two complementary in vitro stimulation strategies. Vaccine 18 (2000) 835-849
26. Gupta, S., Leutenegger, C.M., Dean, G.A., Steckbeck, J.D., Cole, K.S., Sparger, E.E., 2006. Vaccination with attenuated feline immunodeficiency virus proviral DNA vaccine expressing interferon gamma. J. Virol. November 1 [Epub].
27. Storing and purifying antibodies. In: Harlow E., and Lane D. (Eds). Antibodies: A Laboratory Manual (1988), Cold Spring Harbor Laboratory, New York 282-317
28. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., Ortel T.L., Liao H.X., and Alam S.M. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 (2005) 1906-1908
29. Hohdatsu T., Pu R., Torres B.A., Trujillo S., Gardner M.B., and Yamamoto J.K. Passive protection of cats against feline immunodeficiency virus infection. J. Virol. 67 (1993) 2344-2348
30. Hosie M.J., Dunsford T., Klein D., Willett B.J., Cannon C., Osborne R., Macdonald J., Spibey N., Mackay N., Jarrett O., and Neil J.C. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus. J. Virol. 74 (2000) 9403-9411
31. Hosie M.J., Klein D., Binley J.M., Dunsford T.H., Jarrett O., Neil J.C., Knapp E., Giannecchini S., Matteucci D., Bendinelli M., Hoxie J.A., and Willett B.J. Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env. J. Virol. 79 (2005) 1954-1957
32. Huisman W., Schrauwen E.J., Pas S.D., Karlas J.A., Rimmelzwaan G.F., and Osterhaus A.D. Antibodies specific for hypervariable regions 3 to 5 of the feline immunodeficiency virus envelope glycoprotein are not solely responsible for vaccine-induced acceleration of challenge infection in cats. J. Gen. Virol. 85 (2004) 1833-1841
33. Jeras M. The role of in vitro alloreactive T-cell functional tests in the selection of HLA matched and mismatched haematopoietic stem cell donors. Transpl. Immunol. 10 (2002) 205-214
34. Kallel H., Jouini A., Majoul S., and Rourou S. Evaluation of various serum and animal protein free media for the production of a veterinary rabies vaccine in BHK-21 cells. J. Biotechnol. 95 (2002) 195-204
35. Kallel H., Rourou S., Majoul S., and Loukil H. A novel process for the production of a veterinary rabies vaccine in BHK-21 cells grown on microcarriers in a 20-l bioreactor. Appl. Microbiol. Biotechnol. 61 (2003) 441-446
36. Karnasuta C., Paris R.M., Cox J.H., Nitayaphan S., Pitisuttithum P., Thongcharoen P., Brown A.E., Gurunathan S., Tartaglia J., Heyward W.L., McNeil J.G., Birx D.L., de Souza M.S., Thai AIDS Vaccine Evaluation Group, and Thailand. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23 (2005) 2522-2529
37. Kaufmann D.E., Bailey P.M., Sidney J., Wagner B., Norris P.J., Johnston M.N., Cosimi L.A., Addo M.M., Lichterfeld M., Altfeld M., Frahm N., Brander C., Sette A., Walker B.D., and Rosenberg E.S. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J. Virol. 78 (2004) 4463-4477
38. Kusuhara H., Hohdatsu T., Okumura M., Kayoko S., Suzuki Y., Motokawa K., Gemma T., Watanabe R., Huang C., Arai S., and Koyama H. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats. Vet. Microbiol. 108 (2005) 155-165
39. Levy J.A., Scott I., and Mackewicz C. Protection from HIV/AIDS: the importance of innate immunity. Clin. Immunol. 108 (2003) 167-174
40. Li J., Brown W.C., Song W., Carpino M.R., Wolf A.M., Grant C.K., Elder J.H., and Collisson E.W. Retroviral vector-transduced cells expressing the core polyprotein induce feline immunodeficiency virus-specific cytotoxic T-lymphocytes from infected cats. Virus Res. 38 (1995) 93-109
41. Los Alamos National Laboratory. Epitope maps. http://hiv-web.lanl.gov/content/immunology/maps/maps.html/ (accessed October 25, 2006).
42. Matsuo K., Nishino Y., Kimura T., Yamaguchi R., Yamazaki A., Mikami T., and Ikuta K. Highly conserved epitope domain in major core protein p24 is structurally similar among human, simian and feline immunodeficiency viruses. J. Gen. Virol. 73 (1992) 2445-2450
43. Matteucci D., Poli A., Mazzetti P., Sozzi S., Bonci F., Isola P., Zaccaro L., Giannecchini S., Calandrella M., Pistello M., Specter S., and Bendinelli M. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J. Virol. 74 (2000) 10911-10919
44. Miyazawa T. Evolution of lentiviruses and receptor specificity. Uirusu 55 (2005) 27-34
45. Miyazawa T., Tomonaga K., Kawaguchi Y., and Mikami T. The genome of feline immunodeficiency virus. Arch. Virol. 134 (1994) 221-234
46. Mooij P., and Heeney J.L. Rational development of prophylactic HIV vaccines based on structural and regulatory proteins. Vaccine 20 (2001) 304-321
47. Naylor P.H., and Hadden J.W. T cell targeted immune enhancement yields effective T cell adjuvants. Int. Immunopharmacol. 3 (2003) 1205-1215
48. Nishimura Y., Igarashi T., Haigwood N., Sadjadpour R., Plishka R.J., Buckler-White A., Shibata R., and Martin M.A. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76 (2002) 2123-2130
49. Nishimura Y., Igarashi T., Haigwood N.L., Sadjadpour R., Donau O.K., Buckler C., Plishka R.J., Buckler-White A., and Martin M.A. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 15131-15136
50. Nitayaphan S., Pitisuttithum P., Karnasuta C., Eamsila C., de Souza M., Morgan P., Polonis V., Benenson M., VanCott T., Ratto-Kim S., Kim J., Thapinta D., Garner R., Bussaratid V., Singharaj P., el-Habib R., Gurunathan S., Heyward W., Birx D., McNeil J., Brown A.E., and Thai AIDS Vaccine Evaluation Group. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 90 (2004) 702-706
51. Norris P.J., Moffett H.F., Brander C., Allen T.M., O'Sullivan K.M., Cosimi L.A., Kaufmann D.E., Walker B.D., and Rosenberg E.S. Fine specificity and cross-clade reactivity of HIV type I Gag-specific CD4+ T cells. AIDS Res. Hum. Retroviruses 20 (2004) 315-325
52. Omori M., Pu R., Tanabe T., Hou W., Coleman J., Arai M., and Yamamoto J.K. Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine. Vaccine 23 (2004) 386-398
53. Pantophlet R., and Burton D.R. Gp120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24 (2006) 739-769
54. Pistello M., Bonci F., Flynn J.N., Mazzetti P., Isola P., Zabogli E., Camerini V., Matteucci D., Freer G., Pelosi P., and Bendinelli M. AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens. J. Virol. 80 (2006) 8856-8868
55. Pistello M., Bonci F., Isola P., Mazzetti P., Merico A., Zaccaro L., Matteucci D., and Bendinelli M. Evaluation of feline immunodeficiency virus ORF-A mutants as candidate attenuated vaccine. Virology 332 (2005) 676-690
56. Pu R., Okada S., Omori M., Rine S.L., Lewis B.A., Lipton E., Nemcik L., Glass P., and Yamamoto J.K. MHC-restricted protection of cats against FIV infection with adoptive transfer of immunocytes from FIV-vaccinated cats. Cell. Immunol. 198 (1999) 30-43
57. Pu R., Coleman J., Omori M., Mison M., Huang C., Arai M., Tanabe T., and Yamamoto J.K. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS 15 (2001) 1-13
58. Pu R., Paredes G., and Yamamoto J.K. FIV vaccine update (proceeding). Am. Assoc. Feline Practitioners (2004) 103-107
59. ® FIV) protection against heterologous subtype B FIV isolate. Feline Med. Surg. 7 (2005) 65-70
60. Pu R., Sato E., and Yamamoto J.K. Feline immunodeficiency virus (FIV)-cat model for AIDS: T-cell immunity important for prophylactic vaccine protection. Proceedings of the XVI International Conference on AIDS (Abstract THP0016) (2006) 290
61. Quackenbush S.L., Donahue P.R., Dean G.A., Myles M.H., Ackley C.D., Cooper M.D., Mullins J.I., and Hoover E.A. Lymphocyte subset alterations and viral determinants of immunodeficiency disease induction by the feline leukemia virus FeLV-FAIDS. J. Virol. 64 (1990) 5465-5474
62. Richardson J., Broche S., Baud S., Leste-Lasserre T., Femenia F., Levy D., Moraillon A., Pancino G., and Sonigo P. Lymphoid activation: a confounding factor in AIDS vaccine development?. J. Gen. Virol. 83 (2002) 2515-2521
63. Schutz A.M., and Bradac J.A. The HIV vaccine pipeline, from preclinical to phase III. AIDS 15 (2001) S147-S158
64. Seya T., Akazawa T., Tsujita T., and Matsumoto M. Role of Toll-like receptors in adjuvant-augmented immune therapies. Evid. Based Complement Alternat. Med. 3 (2006) 31-38
65. Sirriyah J., Dean G.A., LaVoy A., and Burkhard M.J. Assessment of CD4+ and CD8+ IFN-gamma producing cells by ELISPOT in naïve and FIV-infected cats. Vet. Immunol. Immunopathol. 102 (2004) 77-84
66. Stanhope P.E., Liu A.Y., Pavlat W., Pitha P.M., Clements M.L., and Siliciano R.F. An HIV-1 envelope protein vaccine elicits a functionally complex human CD4+ T cell response that includes cytolytic T lymphocytes. J. Immunol. 150 (1993) 4672-4686
67. Stevens R., Howard K.E., Nordone S., Burkhard M., and Dean G.A. Oral immunization with recombinant Listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus. J. Virol. 78 (2004) 8210-8218
68. Tellier M.C., Pu R., Pollock D., Vitsky A., Tartaglia J., Paoletti E., and Yamamoto J.K. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats. AIDS 12 (1998) 11-18
69. Uhl E.W., Heaton-Jones T., Pu R., and Yamamoto J.K. FIV vaccine development and its importance to veterinary and human medicine: a review. Vet. Immunol. Immunopathol. 90 (2002) 113-132
70. Wallace D., Hildesheim A., and Pinto L.A. Comparison of benchtop microplate beta counters with the traditional gamma counting method for measurement of chromium-51 release in cytotoxic assays. Clin. Diagn. Lab Immunol. 11 (2004) 255-260
71. Yamamoto J.K., Okuda T., Ackley C.D., Louie H., Zochlinski H., Pembroke E., and Gardner M.B. Experimental vaccine protection against feline immunodeficiency virus. AIDS Res. Hum. Retroviruses 7 (1991) 911-922
72. Yamamoto J.K., Hohdatsu T., Olmsted R.A., Pu R., Louie H., Zochlinski H., Acevedo V., Johnson H.M., Soulds G.A., and Gardner M.B. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus. J. Virol. 67 (1993) 601-605
73. Yamamoto J.K. Vaccine for prophylaxis and therapeutics. Wild West Veterinary Conference. Reno, NV, October 9-16, 2002 (2002)
74. Yamamoto J.K., Pu R., Sato E., and Hohdatsu T. Feline immunodeficiency virus pathogenesis and development of a dual-subtype feline-immunodeficiency-virus vaccine. AIDS 21 (2007) 547-563
75. Yuhki N., Heidecker G.F., and O'Brien S.J. Characterization of MHC cDNA clones in the domestic cat. Diversity and evolution of class I genes. J. Immunol. 142 (1989) 3676-3682
76. Yuhki N., and O'Brien S.J. DNA recombination and natural selection pressure sustain genetic sequence diversity of the feline MHC class 1 genes. J. Exp. Med. 172 (1990) 621-630
77. Yuhki N., and O'Brien S.J. Nature and origin of polymorphism in feline MHC class II DRA and DRB genes. J. Immunol. 158 (1997) 2822-2833
78. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 4 (2004) 199-210
79. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 (2001) 10892-10905